

B 3. 12 (New) A polypeptide according to claim 10 comprising at least one of: residues 8-606; residues 18-606; residues 26-606; residues 39-606; residues 48-606; residues 1-601; residues 1-592; residues 1-584; residues 1-573; residues 1-566; residues 24-587; residues 12-568; residues 41-601; residues 6-561; and residues 55-605 of SEQ ID NO:2. L L

4. 13. (New) A polypeptide according to claim 10 comprising SEQ ID NO:2.

14. (New) A polypeptide made by a method comprising incubating a host cell or cellular extract containing a recombinant nucleic acid comprising a coding region encoding a polypeptide according to claim 10 under conditions whereby the polypeptide is expressed, wherein said coding region is flanked by fewer than 2 kb of native flanking sequence.

15. (New) A polypeptide made by a method comprising incubating a host cell or cellular extract containing a recombinant nucleic acid comprising a coding region encoding a polypeptide according to claim 11 under conditions whereby the polypeptide is expressed, wherein said coding region is flanked by fewer than 2 kb of native flanking sequence.

A
16. (New) A polypeptide made by a method comprising incubating a host cell or cellular extract containing a recombinant nucleic acid comprising a coding region encoding a polypeptide according to claim 12 under conditions whereby the polypeptide is expressed, wherein said coding region is flanked by fewer than 2 kb of native flanking sequence.

17. (New) A polypeptide made by a method comprising incubating a host cell or cellular extract containing a recombinant nucleic acid comprising a coding region encoding a polypeptide according to claim 13 under conditions whereby the polypeptide is expressed, wherein said coding region is flanked by fewer than 2 kb of native flanking sequence.

18. (New) A polypeptide according to claim 17, said coding region comprising nucleotides 1-1902 of SEQ ID NO:1.

19. (New) A method for modulating a cellular physiology, said method comprising the step

Sub D1

2.

Serial No. 09/041,236

34

A

of contacting a cell with an agent which modulates sema K1 activity and thereby modulates the cell's physiology, wherein the agent comprises a polypeptide according to claim 10.

Sub D
cont

20. (New) A method for modulating a cellular physiology, said method comprising the step of contacting a cell with an agent which modulates sema K1 activity and thereby modulates the cell's physiology, wherein the agent comprises a polypeptide according to claim 11.

A
cont

21. (New) A method for modulating a cellular physiology, said method comprising the step of contacting a cell with an agent which modulates sema K1 activity and thereby modulates the cell's physiology, wherein the agent comprises a polypeptide according to claim 12.

22. (New) A method for modulating a cellular physiology, said method comprising the step of contacting a cell with an agent which modulates sema K1 activity and thereby modulates the cell's physiology, wherein the agent comprises a polypeptide according to claim 13.

REMARKS

Support for the recited fragments of SEQ ID NO:2 are found on p.5-6 (Tables 1 and 2). Support for the 2kb flanking region limitations is found on page 10, lines 22. These amendments introduce no new matter.

We confirm election of group I. Upon allowability of the product claims of Group I, Applicants request rejoinder of non-elected Group III claims 19-22 (in the case of an elected product claim, rejoinder will be permitted when a product claim is found allowable and the withdrawn process claim depends from or otherwise includes all the limitations of an allowed product claim, per Commissioner Lehman's Notice of February 28, 1996: Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. 103(b)).

The oath is believed to be in compliance with 37CFR1.67(a). The Action indicates that the inventor's original signatures are lacking. We believe that the application number, filing date and inventors signatures are present on the oath and request clarification of this objection.

The claims are believed to be in compliance with 37CFR1.75(c). Dependent claims are construed to contain all the limitations of the parent claim. While claim 2 has been canceled, we